Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Biomarker testing has fundamentally changed how doctors detect Alzheimer’s disease, moving from a diagnosis that could only be confirmed after death to one that can be identified years or even decades before symptoms appear. Recent advances in blood tests and imaging biomarkers now allow clinicians to identify the hallmark proteins of Alzheimer’s—amyloid-beta, tau, and phosphorylated tau—with unprecedented accuracy and accessibility. For example, a 55-year-old person with a family history of Alzheimer’s can now have a simple blood test performed at their doctor’s office that reveals whether amyloid plaques are accumulating in their brain, providing actionable information that wasn’t available just five years ago.
These improvements represent a major shift in dementia care. Where physicians once relied on cognitive testing and imaging to diagnose Alzheimer’s only after cognitive decline had begun, they can now identify the disease’s biological signature while a person is still cognitively normal. This early detection window opens possibilities for intervention during the stages when treatments may have the greatest impact, before irreversible brain damage has occurred.
Table of Contents
- What Are Alzheimer’s Biomarkers and Why Do They Matter?
- Blood-Based Biomarkers: Making Detection Accessible
- PET Imaging and Cerebrospinal Fluid Biomarkers: The Detailed Picture
- Using Biomarkers in Clinical Practice: When and How to Test
- Genetic Risk Factors and Biomarker Interpretation
- Biomarkers Beyond Amyloid and Tau
- The Future of Biomarker-Driven Dementia Care
- Conclusion
What Are Alzheimer’s Biomarkers and Why Do They Matter?
Alzheimer’s biomarkers are measurable biological indicators of disease pathology—physical evidence that the characteristic proteins of Alzheimer’s are damaging brain cells. The disease is defined by two main pathological features: amyloid-beta plaques that accumulate outside neurons and tau tangles that form inside them. For decades, the only way to definitively confirm these were present was through autopsy.
Biomarkers changed that by making it possible to detect these pathological changes during a person’s lifetime through blood tests, cerebrospinal fluid analysis, and positron emission tomography (PET) imaging. The importance of biomarkers lies in their ability to identify Alzheimer’s in asymptomatic individuals—people who have no memory problems or cognitive decline but whose brains are already showing pathological changes. This distinction matters because Alzheimer’s is now understood as a continuum that can exist for 10 to 20 years before someone experiences noticeable cognitive symptoms. Someone with normal cognition but positive biomarkers is said to have “preclinical Alzheimer’s disease.” This expanded understanding of the disease has allowed researchers to enroll participants in clinical trials earlier in the disease process, leading to the development of treatments like lecanemab and donanemab that can slow cognitive decline when given in the early stages.
Blood-Based Biomarkers: Making Detection Accessible
Blood biomarkers represent the most significant recent breakthrough in Alzheimer’s detection because they are non-invasive, relatively inexpensive, and can be performed in routine clinical settings. The primary blood biomarkers include phosphorylated tau variants (p-tau181 and p-tau217), plasma phosphorylated tau (p-tau), amyloid-beta 42, and neurofilament light chain (NfL), a marker of neurodegeneration. A recent landmark study showed that blood biomarkers were nearly as accurate as PET imaging—the gold standard for detecting brain amyloid—while being far more practical for widespread screening.
However, a significant limitation of blood biomarkers is that they detect the presence of disease pathology but don’t always tell clinicians exactly where in the brain the damage is occurring or how advanced the process is. Additionally, biomarkers can remain positive without necessarily causing cognitive symptoms for years. A positive biomarker result creates what some researchers call the “worried well” problem: cognitively normal individuals learn they have brain pathology but no symptoms, no approved preventive treatments available to everyone, and uncertain prognosis. This creates a counseling challenge for clinicians and potential anxiety for patients, and decisions about how and whether to test asymptomatic individuals remain controversial.
PET Imaging and Cerebrospinal Fluid Biomarkers: The Detailed Picture
PET imaging provides spatial information about where amyloid and tau are accumulating in the brain, showing patterns that can help differentiate Alzheimer’s disease from other dementias. Amyloid PET scans reveal whether plaques are present, while tau PET scans show where tau tangles have accumulated. This information can be clinically valuable because tau distribution patterns sometimes help distinguish Alzheimer’s from other neurodegenerative diseases. For instance, primary age-related tauopathy (PART) shows tau tangles in memory centers but little amyloid, while Alzheimer’s typically shows both.
Cerebrospinal fluid (CSF) biomarkers—measured through lumbar puncture—remain highly accurate and can detect the amyloid/tau pathology ratio that characterizes Alzheimer’s. However, lumbar puncture is invasive and uncomfortable, limiting its routine clinical use to specialized centers and research settings. The emergence of blood biomarkers has therefore shifted the landscape, with CSF testing now reserved primarily for complex diagnostic cases or research studies. One important caveat: not all abnormal biomarkers mean a person has or will develop Alzheimer’s disease. Some individuals with amyloid pathology never develop cognitive symptoms, possibly due to protective factors like cognitive reserve or genetic differences.
Using Biomarkers in Clinical Practice: When and How to Test
The practical application of biomarker testing in clinical care involves thoughtful patient selection rather than blanket screening. Current expert consensus recommends biomarker testing for individuals with cognitive complaints or cognitive decline, people with cognitive concerns noted by family members, and potentially asymptomatic individuals with a strong family history of dementia who specifically request testing. In clinical practice, a physician might first obtain blood biomarkers to screen for Alzheimer’s pathology, and if results are positive, follow up with cognitive testing and potentially imaging to better characterize disease stage.
A major consideration is that biomarker-positive asymptomatic individuals now become candidates for disease-modifying treatments like lecanemab (Leqembi) and donanemab (Kisunla), which have been shown to slow cognitive decline in people with mild cognitive impairment or mild dementia with amyloid pathology. The tradeoff is that these treatments require regular intravenous infusions or infusions, cost tens of thousands of dollars annually, and carry a risk of amyloid-related imaging abnormalities (ARIA)—brain microhemorrhages or microinfarcts that can occasionally cause symptoms. Therefore, the decision to test and potentially treat must be made collaboratively with patients who understand both the benefits and risks.
Genetic Risk Factors and Biomarker Interpretation
Genetic testing, particularly for the APOE4 gene variant, often accompanies biomarker evaluation since APOE4 is the strongest genetic risk factor for late-onset Alzheimer’s disease. People who carry one APOE4 copy have increased risk, and those with two copies have substantially elevated risk. Knowledge of APOE4 status can contextualize biomarker results—an APOE4 carrier with positive amyloid biomarkers may have greater concern for future cognitive decline than someone without the genetic risk variant. However, APOE4 status alone doesn’t predict who will develop cognitive symptoms.
Approximately 30% of cognitively normal people are APOE4 carriers, and not all will develop dementia. A critical limitation is that biomarker positivity and genetic risk don’t automatically indicate who will progress to cognitive impairment and when. Someone could have amyloid pathology, positive biomarkers, and the APOE4 gene but remain cognitively normal for decades—or even die with Alzheimer’s pathology without having experienced dementia in life. This unpredictability creates ethical dilemmas around communicating test results to asymptomatic individuals. Additionally, APOE4 testing raises privacy concerns since genetic information can have implications beyond dementia risk, making counseling an essential component of the testing process.
Biomarkers Beyond Amyloid and Tau
Research is expanding beyond the traditional amyloid and tau biomarkers to identify other pathological processes in Alzheimer’s disease, including neuroinflammation, mitochondrial dysfunction, and vascular changes. Plasma phosphorylated tau variants like p-tau217 appear to correlate more strongly with cognitive decline than older p-tau181 measures, and emerging biomarkers such as glial fibrillary acidic protein (GFAP) and YKL-40, which reflect neuroinflammation, may provide additional prognostic information. These next-generation biomarkers are being incorporated into research studies to better predict who among biomarker-positive individuals will progress to cognitive impairment and at what rate.
A real-world example of this expanding approach is the Amyloid Biomarker Study and the ongoing ADCOMS initiative, which use combinations of multiple biomarkers to predict cognitive decline more accurately than any single biomarker alone. However, these advanced biomarker panels are still primarily used in research settings and specialized dementia centers, not yet in routine primary care practice. As these biomarkers become more accessible and affordable, they may eventually enable more personalized risk stratification and treatment selection.
The Future of Biomarker-Driven Dementia Care
The trajectory of Alzheimer’s biomarker science points toward increasingly accessible testing, earlier detection, and treatment during the asymptomatic phase of disease. As blood biomarkers become standardized and incorporated into commercial laboratory menus, testing may eventually migrate to primary care settings, similar to how cholesterol screening is now routine. Advanced biomarker combinations may eventually enable prediction of who will progress within specific timeframes, allowing more targeted prevention and intervention.
However, the future of biomarker-driven care also requires solving the challenge of equitable access. Currently, advanced biomarker testing is concentrated in academic medical centers and affluent areas, while underserved populations lack access. Additionally, the field must continue developing and validating biomarker-guided treatment strategies that balance clinical benefit against cost and risk. Clinical trials underway—including AHEAD and CLARITY AD—are examining whether biomarker-guided treatment in asymptomatic and mildly symptomatic individuals can meaningfully prevent or delay dementia, results that will shape standard of care over the next several years.
Conclusion
Biomarker improvements have transformed Alzheimer’s disease from a condition that could only be definitively diagnosed at autopsy into one that can be identified in its preclinical stages through accessible blood tests and imaging. These advances enable identification of people at highest risk for cognitive decline and allow for earlier intervention with disease-modifying treatments. Yet the widespread adoption of biomarker testing in clinical practice requires careful consideration of the implications for asymptomatic individuals, informed consent processes that address both benefits and limitations, and ongoing research to determine which treatment strategies provide lasting clinical benefit.
If you are concerned about dementia risk—whether because of family history, cognitive concerns, or simply advanced age—discussing biomarker testing with your physician is now a reasonable option. Your doctor can assess whether testing is appropriate for your situation, help interpret results if testing is performed, and discuss what positive or negative results mean for your individual risk and potential next steps. The goal of biomarker testing is not to create worry, but to provide information that enables informed decisions about brain health.
